stringent criteria used by CMS for sepsis and extended the CMS criteria to identify the remaining 4 conditions to 10 discharge diagnoses fields. We estimated costs for readmissions using previous approaches. 5 We performed pairwise comparisons of proportions of index admissions, length of stay, and cost for each of the 5 conditions using multinomial logistic, negative binomial, and γ regression, respectively. For all analyses, robust standard errors were used, and 2-sided P values less than .005 were considered significant to account for multiple comparisons. All statistical analyses were performed using SAS (SAS Institute), version 9.3, and Stata (StataCorp), version 13.1.
b Of the selected 3880 women diagnosed with early-stage breast cancer between July 2013 and September 2014, 249 were ineligible due to having a prior breast cancer diagnosis or stages III-IV, residing outside the SEER registry area, or being deceased, too ill, or unable to complete a survey in Spanish or English. Of 3631 eligible women remaining, 1053 could not be contacted or did not participate. Of 2578 patients who responded (71%), 49 were ineligible because of genetic testing before their diagnosis, leaving 2529 for the study sample.
c Patients were categorized as high risk if they had 1 or more of the following: 45 years or younger at breast cancer diagnosis; bilateral breast cancer; triple-negative breast cancer diagnosed at 60 years or younger; any relative with ovarian cancer, sarcoma, or male breast cancer; 2 or more first-degree relatives with breast cancer; for patients diagnosed at age Յ50: 1 or more first-degree relative with breast cancer; Ashkenazi Jewish ancestry; or family history of a deleterious genetic mutation (BRCA1 or BRCA2 or another mutation associated with increased breast cancer risk [eg, TP53] ). All other patients were categorized as average risk.
d Survey design and nonresponse weights were created to compensate for the differential probability of selecting patients by race, stage, and SEER site and to adjust for survey nonresponse. The weights were normalized to equal the observed sample size and all analyses were weighted.
e Univariate log-linear models were corrected for multiple imputation.
f A multivariable log-linear model (Poisson distribution with log link) was used that was corrected for multiple imputation and used robust standard error estimation. Survey and SEER item nonresponse was low (<4%) for most covariates and higher for self-reported income (17%). To correct for potential nonresponse bias, values for missing items were imputed using sequential multiple imputation. Results were compared between sequential multiple imputation analyses and complete-case analyses for any meaningful differences. The model was simultaneously adjusted for the covariates listed within Table 1 Clinical need for genetic testing may not be adequately recognized by physicians. High-risk patients reported lack of a physician's recommendation, not expense, as their primary reason for not testing. Limitations of the study included the testing data source being by patient self-report and that the patients lived in only 2 geographic regions. The findings emphasize the importance of cancer physicians in the genetic testing process. Priorities include improving physicians' communication skills and assessments of patients' risk and desire for testing, and optimizing triage to genetic counselors. weeks, the beneficial effect of 100 U decreases rapidly. Second, patients with idiopathic overactive bladder receive an injection of 100 U of onabotulinumtoxinA usually twice a year. In our practice, many patients ask after a few years for a more definitive solution, because they do not want to receive regular injections under general or local anesthesia for the rest of their lives. Most patients choose to receive sacral neuromodulation with a battery, which has to be replaced every 5 years. Therefore, this study would benefit from a longer follow-up to provide more detailed information on patient preferences.
Third, the study group included only patients who had 2 or more urgency incontinence episodes per day. Such symptoms are usually reported by older patients with severe leakage who represent about 20% of those in the population of patients with idiopathic overactive bladder.
3 Patients with overactive bladder without incontinence do not have another disease compared with overactive bladder with incontinence, but they are usually younger, more mobile, and able to reach the toilet in time. This may explain why the mean age of the patients was higher than reported in other studies on sacral neuromodulation. 4, 5 Because most patients with overactive bladder were excluded, this study covers only a small selection of patients on the overactive bladder spectrum, and the results cannot be extrapolated to all patients with overactive bladder.
Bertil F. M. Blok, MD, PhD
Author Affiliation: Department of Urology, Erasmus Medical Center, Rotterdam, the Netherlands. 
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 Yes
 Mark only one response for each question unless other instructions are given, such as "Mark ALL that apply".
 Please follow any instructions or arrows that direct you to the next question.
Example:
 No
Please go to F9 on the next page.
 If you mark an answer with a line after it, please write the specific information on the line.
Example:
Other (please explain):
General Instructions PLEASE READ THESE INSTRUCTIONS CAREFULLY
Please be reminded that your responses to this survey are confidential and will not be shared with your doctors. Have you ever had a blood or saliva genetic test for breast cancer risk that was ordered by a doctor?
C
Please mark "yes", "no", or "don't know" and then follow the arrow. I did not have any mutations in the gene tests I had a mutation in a gene that increases the risk of breast cancer (BRCA1 or BRCA2)
Yes
A gene mutation was found, but not one that has been shown to increase the risk of breast cancer I don't know the results Other (please explain): I did not have any lymph nodes removed I had a sentinel node biopsy ONLY -where a radioactive material or blue dye was injected into the breast and only one or a few lymph nodes in the armpit were removed I had a complete axillary dissection -where all or most of the lymph nodes were removed
I don't know
A. How were all or most of the lymph nodes removed? Please mark ONE.
I had a needle biopsy before my surgery that showed cancer in the lymph nodes under the armpit, so all of the lymph nodes were taken out later during my surgery I had a single operation in which my sentinel nodes were tested and found to have cancer, so all of the lymph nodes were taken out at that time I had a single operation in which all of my lymph nodes were removedno needle biopsy or sentinel node testing was done My sentinel nodes were found to have cancer during a first operation, so I had a second, separate operation to remove all of the lymph nodes I'm not sure how the lymph nodes were removed C9. At the time of your breast cancer diagnosis, how much time did it take you to get from your home to the nearest hospital? 
Radiation Therapy
C12. Did you have radiation therapy to treat your breast cancer?
Please mark "yes", "no", or "not yet" and then follow the arrow. Please mark ALL that apply.
Yes
My whole breast
Only the part of the breast where my tumor was
The chest wall, after my mastectomy Please mark ALL that apply.
My doctor(s) did not discuss it with me My doctor(s) said I didn't need it
My doctor(s) left it up to me and I chose not to I was worried about side effects or complications I was worried about the cost It would have been too much of a burden on me or my family Have you or are you going to be taking any of these medications? Please mark ONE.
Yes, I currently take one of these medications
Yes, I took one of these medications before but no longer take it Yes, I plan to take one of these medications in the future but haven't started yet
No, I am not taking any of these medications right now and I am unsure whether or not I should start
No, I have no plans to take any of these medications
Clinical Trial Participation
Clinical trials are research studies that involve patients. 
Section I: Your Thoughts and Feelings
The questions below are important to help us better understand how women like you feel towards the end of treatment and the beginning of the recovery period. Please answer these questions the best way you can.
I1. How likely do you think it is that your breast cancer will come back?
Not at all likely A little likely Somewhat likely Quite likely Very likely I2. For the question below, please write in a number from 0% to 100% where… 0% = you think there is absolutely no chance that your breast cancer will come back in the breast or the area around it in the next 10 years, and 100% = you think it is absolutely certain that your breast cancer will come back in the breast or the area around it in the next 10 years
After receiving all the planned treatments, what do you think is the chance that your cancer will come back in the breast or the area around it within 10 years?
I3. After receiving all of the planned treatments, do you consider your risk of the cancer coming back in the breast or the area around it to be:
Very low Low Moderate High Very high ________ % (0 to 100) I4. Next, we would like to ask you for your opinion on the chances of your cancer spreading to other parts of your body. For the question below, please write in a number from 0% to 100% where… 0% = you think there is absolutely no chance that your breast cancer will spread to other parts of your body in the next 10 years, and 100% = you think it is absolutely certain that your breast cancer will spread to other parts of your body in the next 10 years
After receiving all the planned treatments, what do you think is the chance that your cancer will spread to other parts of your body within 10 years?
I5. After receiving all the planned treatments, do you consider your risk of the cancer spreading to other parts of your body to be: 
